Kornimate/medical-research-clean huggingface dataset:
neuro-covid-19: neurological complications of covid-19

Conditions: Neurologic Complication

Summary: the prevalence and typical patterns of neurological complications in hospitalized covid-19 patients admitted to the intensive care units of the university hospital zurich will be investigated. the impact of neurological complications among covid-19 patients on mortality, functional outcome, and organizational outcomes will be analyzed.

this study is a prospective observational cohort study to document prevalence and severity of neurological symptoms among patients requiring critical care admission for confirmed novel coronavirus disease (covid-19). covid-19 is classified as severe acute respiratory syndrome 2 (sars-cov-2) and shares significant structural and biological similarities with sars-cov, which has neuroinvasive properties and brainstem involvement. early reports of covid-19 progression indicate presence of severe neurological complications, including seizures, coma, encephalitis, and cerebrovascular events including ischemic stroke, intracranial hemorrhage, and cerebral venous sinus thromboses. in addition, recent data from zika-virus and h1n1 influenza pandemics reveal a high incidence of neurological complications, including guillain barré syndrome and neonatal microcephaly for zika-virus and narcolepsy with h1n1 infections. early reports from china suggest neurological symptoms may occur in approximately 36% of sars-cov-2 positive patients, with increased prevalence among more severe cases, and fall into three categories: central nervous system symptoms or diseases, peripheral nervous system symptoms, and skeletal muscular symptoms. however, the exact prevalence of these conditions and impact on patient disease severity and outcomes is unknown. as the incidence and severity of covid-19 infection continues to rapidly rise on an international level, it is imperative to capture prospective data to accurately document prevalence, severity and clinical characterization of neurological components of covid-19, the influence of treatment regimens of neurological complications, and role of these confounders on patient and organizational outcomes.

Eligibility criteria:
inclusion criteria: * adults (age \> 18 years old) treated at icus * admitted with confirmed covid-19 infection * patient exhibiting acute neurological manifestations * general consent of the institute of intensive care medicine available from patient or legal representative exclusion criteria: * pre-existing severe neurologic dysfunction
outpatient treatment of patients with morbid obesity - a two-year follow up

Conditions: Morbid Obesity

Summary: this study is a pilot project to investigate any effect on these markers in conjunction with lifestyle changes / conservative treatment. useful and significant information in this pilot project is intended to be used as background for further research on this issue in connection with a doctorate. what is the effect of two years of outpatient treatment for lifestyle change for weight markers, waist, bmi, hba1c, hdl and ldl cholesterol, triglycerides and uric acid in adults with morbid obesity?


Eligibility criteria:
inclusion criteria: * adults from 18 - 60 years, both sex

Keywords: obesity adults lifestyle intervention effect after two years treatment for lifestyle change - morbid obesity adults
combined effects of barre and gym ball exercises in primary dysmenorhoea

Conditions: Dysmenorrhea Primary

Summary: group a will be given barre and gym ball exercises. group b will be given barre exercises. all these sessions will be of 30-minute 3session per week for 12 weeks.

this will be a randomized controlled trial conducted on 42 participants. data will be collected from uskt (university of sialkot) and umt (university of management and technology sialkot by using non-probability convenience sampling technique. wallid score scale is used to determine the severity of dysmenorrhoea. girls between the age of 17 to 25 with history of dysmenorrhea will be included in this study. participants who has history of secondary dysmenorrhea, diagnosed with polycystic ovarian syndrome will be excluded from this study. a sample of 42 will be divided in to two groups with 21 participants in each group. group a will be given barre and gym ball exercises. group b will be given barre exercises. all these sessions will be of 30 minute 3session per week for 12 weeks. pre and post assessment of pain, distress , severity of dysmenorrhoea and quality of life will be done by using numeric pain rating scale, menstrual distress questionnaire, wallid scale and q-les-q-sf questionnaire. data will be analyzed by using spss version 26.0.

Eligibility criteria:
inclusion criteria: * female suffered from primary dysmenorrhea diagnosed through wallid score range from 5-12 * female having 5 and above score on numerical pain rating scale * female having regular menstrual period form at least 3 months * female having a history of dysmenorrhea occurring at least three times in the past six months exclusion criteria: * females using hormonal contraception. * females who are married. * females with secondary dysmenorrhea * females diagnosed with polycystic ovarian syndrome * females having menstrual issues * females who take analgesic * females having bmi \> 25 * participants who show unwillingness to participate in the study

Keywords: gym exercises quality of life dysmenorrhea menstrual cycle female
remote neurocognitive and psychological assessment in pku

Conditions: Phenylketonurias

Summary: pku is a rare autosomal recessive condition associated with disruption in dopamine synthesis. although early diagnosis and treatment prevent the severe impairments associated with untreated pku, individuals with early-treated pku (etpku) nonetheless experience significant sequelae, including impaired working memory and increased risk for anxiety problems. past research with other clinical populations (e.g., generalized anxiety disorder) suggests that the two phenomena may be linked, with increased anxiety contributing to poorer wm performance. currently we propose to initiate an exciting new line of research examining the potential relationship between anxiety and wm in etpku. the proposed study will also apply remote neuropsychological performance-based assessment to the study of etpku and thus overcoming the geographical limitations/challenges associated with recruitment of participants with this rare disease.


Eligibility criteria:
inclusion criteria: * participants with pku will be included if they were diagnosed as newborns and immediately started on treatment. exclusion criteria: * individuals with a history of neurologic compromise or major medical disorder unrelated to pku (e.g., closed head injury, diabetes, multiple sclerosis) will be excluded. in addition, individuals with pku will be excluded if they are on a medication called peg-valiant/ peg-pal/ pegvaliase/palynziq.
vascular responses to high vs low repetition resistance exercise training in young men

Conditions: Weight-Lifting Exercise Program

Summary: this study evaluates the effects of two types of resistance exercise training (higher-repetition, lower load vs lower-repetition, higher load vs control) on regional and local measures of arterial stiffness in trained young men.


Eligibility criteria:
inclusion criteria: * male * aged 18-30 years old * non-obese (body mass index less than 30 kg/m2) * non-smoker * healthy based on questionnaire responses * resistance trained (resistance training \> 2 times per week for 2 years, minimum 1 lower body exercise session per week) exclusion criteria: * allergies to milk proteins (whey or casein) * any acute or chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin- or non-insulin dependent diabetes or other metabolic disorders-all ascertained through medical history screening questionnaires * arthritic conditions * individuals who consume any analgesic or anti-inflammatory drug(s), prescription or non- prescription, chronically will be excluded * a history of neuromuscular problems * individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
dosage reduction and acute glycemic complications in people with type 2 diabetes who fast during ramadan

Conditions: Diabetes Mellitus, Type 2

Summary: every lunar year, during the month of ramadan, muslims abstain from food and drink between dawn and nightfall. people with type 2 diabetes who fast during ramadan are at an increased risk of acute glycemic complications. our aim is to investigate the effect of dosage reduction of four glucose-lowering multidrug regimens on the incidence of acute glycemic complications in people with type 2 diabetes who fast during ramadan.


Eligibility criteria:
inclusion criteria: * prospective participant is a returning patient with type 2 diabetes; * prospective participant expressed an intention to fast during ramadan; * prospective participant has been compliant with one of four glucose-lowering multidrug regimens for at least the past three months. exclusion criteria: * prospective participant is a pregnant, postpartum, breastfeeding, or eumenorrheic woman; * prospective participant has experienced diabetic ketoacidosis or hyperosmolar hyperglycemic state within three months; * prospective participant has received niacin or corticosteroids within one month; and, * prospective participant has any history of recurrent hypoglycemia, hypoglycemia unawareness, chronic renal insufficiency (stages iv or v), liver cirrhosis, uncontrolled epilepsy, depressive disorder, bipolar disorder, psychotic disorder, or cognitive dysfunction.

Keywords: diabetes mellitus, type 2 fasting hypoglycemic agents hypoglycemia hyperglycemia diabetic ketoacidosis hyperglycemic hyperosmolar nonketotic coma metformin glimepiride vildagliptin insulin glargine insulin, regular, human
treatment with su11248 in patients with neuroendocrine tumors

Conditions: Neuroendocrine Tumors

Summary: to assess the safety and efficacy of su11248 in patients with neuroendocrine tumors.


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven diagnosis of carcinoid tumor or pancreatic islet cell tumor. * evidence of unidimensionally measurable disease as per response evaluation criteria in solid tumors (recist). * ecog performance status 0 or 1 exclusion criteria: * diagnosis of small-cell carcinoma, pheochromocytoma/paraganglioma, merkel cell carcinoma, or any other second malignancy within the last 5 years except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri. * prior treatment with any tyrosine kinase inhibitors or anti-vegf angiogenic inhibitors. prior treatment with non-vegf-targeted angiogenic inhibitors is permitted.

Keywords: neuroendocrine tumor, advanced disease, sunitinib, phase 2
upper limb function and visuospatial exploration after stroke

Conditions: Stroke

Summary: this project is a cross-sectional, observational mono-center study with prospective data collecting. this study aims to further explore quality of upper limb movement in relation to characteristics of visuospatial exploration in stroke subjects and healthy subjects by a applying comprehensive measurements of clinical scales and kinematic data in capacity- and performance-based activities. the results will contribute to assessing and monitoring quality of upper limb movements and visuospatial attention and their relationship.


Eligibility criteria:
inclusion criteria: * subjects of 18 years and older with chronic ischemic stroke (\> 6 month) restricted to one hemisphere (confirmed by ct/mri) * with impairments in upper limb function and at least partial ability to lift the arm against gravity, flex and extend the fingers * without relevant pre-existing limitations in arm and hand function (orthopaedic, muscular, neurologic) * written informed consent after participants's information exclusion criteria: * increased muscle tone in the upper limb with limited rang of motion * severe sensory deficits in the upper limb * clinically significant concomitant disease (affecting the upper limb or impaired vision, e.g. due to glaucoma etc.) * contraindications on ethical grounds (vulnerable persons) * known or suspected non-compliance, drug or alcohol abuse * severe communication or cognitive deficits, that cause inability to follow the procedures

Keywords: synergies upper limb vision
inreal - nintedanib for changes in dyspnea and cough in patients suffering from chronic fibrosing interstitial lung disease (ild) with a progressive phenotype in everyday clinical practice: a real-world evaluation

Conditions: Lung Diseases, Interstitial

Summary: the primary objective of this observational study is to investigate the correlation between changes from baseline at 52 weeks in forced vital capacity (fvc) and changes from baseline at 52 weeks in dyspnea score points or cough score points as measured with the pulmonary fibrosis questionnaire (l-pf) questionnaire over 52 weeks of nintedanib treatment in patients suffering from chronic fibrosing interstitial lung disease (ild) with a progressive phenotype (excluding idiopathic pulmonary fibrosis (ipf)).


Eligibility criteria:
inclusion criteria: * adults ≥ 18 years at visit 1 * subjects must be contractually capable and mentally able to understand and follow the instructions of the study personnel * physician's diagnosis of chronic fibrosing interstitial lung disease (ild) with a progressive phenotype, except idiopathic pulmonary fibrosis (ipf) * treatment with nintedanib in inreal will be the first and only prescription of any antifibrotic treatment for each individual patient within this observational study after a physician's decision being made for this treatment option earlier * outpatients not currently hospitalized with a life expectancy \> 12 months per investigator's assessment * written informed consent prior to study participation * current forced vital capacity (fvc) measurement (taken within the last 3 months) available in the patient file * women of childbearing potential must take appropriate precautions against getting pregnant during the intake of nintedanib exclusion criteria: * patients with contraindications according to summary of product characteristics (smpc) * prior use of any antifibrotic treatment * lack of informed consent * pregnant or lactating females * any physician diagnosed exacerbation of ild in the patient's history file, irrespective of time since event * current diagnosis of lung cancer * respiratory failure (ph \ 30/min) in the patient's history * participation in a parallel interventional clinical trial * patients being spouse or lateral relatives to the second degree or economically dependent from the investigator
big data and text-mining technologies applied for breast cancer medical data analysis

Conditions: Breast Cancer

Summary: primary purpose : to develop a method to automatically extract and structure the information included in numerous medical records from breast cancer patients. secondary purpose : with this procedure we can analyze the content of ten thousand anonymized textual medical records. this information should enable us to explore many subjects, such as: * the impact of certain therapeutic procedures * the characteristics of sub-groups of patients * pregnancy associated breast cancers * risk factors


Eligibility criteria:
inclusion criteria: * majority (age \> 18) * malignant breast tumors * signed informed consent exclusion criteria: * benign breast pathology * patients not initially treated at the hôpitaux universitaires de strasbourg

Keywords: breast cancer text mining big data machine learning
study of lumacaftor in combination with ivacaftor in subjects with moderate hepatic impairment and healthy subjects

Conditions: Hepatic Impairment; Healthy

Summary: this study is designed to evaluate the pharmacokinetics (pk) and safety of multiple doses of lumacaftor in combination with ivacaftor in subjects with moderate hepatic impairment.


Eligibility criteria:
inclusion criteria: group a: subjects with moderate hepatic impairment * male and female 18 to 65 years of age (inclusive) * satisfy the criteria for moderate hepatic impairment defined as a child pugh total score of 7 to 9 (child pugh class b) at the screening visit * willing and able to comply with schedule visits, treatment, laboratory tests, and contraceptive guidelines. group b: healthy subjects * male and female 18 to 65 years of age (inclusive) * healthy subjects with no clinically relevant abnormalities identified by a detailed medical history, complete physical examination, including blood pressure and pulse rate measurement, standard 12-lead ecg, and clinical laboratory tests * willing and able to comply with schedule visits, treatment, laboratory tests, contraceptive guidelines and other study procedures exclusion criteria: group a: subjects with moderate hepatic impairment * history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject * have fluctuating or rapidly deteriorating hepatic function by history or as indicated by significant variations in or worsening of clinical and/or laboratory signs of hepatic impairment within 6 months before the screening visit * other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver * severe hepatic encephalopathy * type 1 diabetes mellitus or evidence of poorly controlled type 2 diabetes * hepatocellular carcinoma, hiv, hepatitis b/c * significant renal dysfunction * solid organ or bone marrow transplantation * history of regular alcohol consumption, drug abuse or regular smoking group b: healthy subjects * history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject * history of regular alcohol consumption, drug abuse or regular smoking

Keywords: pharmacokinetics, hepatic impairment
effect of white light on fatigue levels in patients with gynecological cancer

Conditions: Cancer-related Fatigue; Light; Therapy, Complications

Summary: white light therapy is one of the non-pharmacological methods in the management of fatigue. cancer-related fatigue (crf) is a persistent, subjective sense of physical, emotional, and/or cognitive tiredness or burnout. it is associated with cancer or cancer treatment from the first diagnosis until the end of life that is not proportional to recent physical activity. it was founded that 10,000 lux bright white light administered in the morning hours reduced fatigue by 17% in patients with cancer and that the mean fatigue scores of patients decreased from 30.37 to 9.48 compared to before the light administration. according to nccn (2020), white light of 10,000 lux can be applied for 30-90 minutes in the morning hours to regulate sleep and manage fatigue in the post treatment period as well as in cancer patients receiving active treatment. however, studies on this subject consist of small sample groups, and more studies are needed to identify the risks and benefits of the application and to determine the optimal application time and duration. the present study was aimed to evaluate the effect of white light on the fatigue levels of patients with gynecological cancer who were treated with chemotherapy. the patients with high levels of fatigue in every dimension were selected so as to have a homogeneous group. the research hypotheses were determined as follows: h0: white light has no effect on fatigue levels in patients with gynecological cancer. h1: white light reduces fatigue levels in patients with gynecological cancer.


Eligibility criteria:
inclusion criteria: * had a normal state of consciousness, * had no communication disorders, did not work in the night shift, * had a general fatigue level score of ≥1 according to the brief fatigue inventory exclusion criteria: * had natural/artificial lenses, * used medication that causes photosensitivity (tetracycline, doxycycline, nalidixic acid, voriconazole, amiodarone, hydrochlorothiazide, naproxen, piroxicam, chlorpromazine) * had a change in their treatment plan in the last 6 weeks were not included in the study

Keywords: cancer-related fatigue white light therapy chemotherapy clinical trial
dextromethorphan in chemotherapy-induced peripheral neuropathy management

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: the aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.

this is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing dextromethorphan and placebo for the treatment of chemotherapy-induced peripheral neuropathy, assessed with a (0-10) numerical scale. cognition, anxiety, depression, sleep and quality of life are also assessed. the influence of cyp2d6, cyp3a4 and mdr1 polymorphism on the dextromethorphan analgesic efficacy will be measured.

Eligibility criteria:
inclusion criteria: * - age ≥ 18 years * breast cancer patients suffering from chemotherapy-induced peripheral neuropathy for at least 3 months after the end of their last cancer chemotherapy * numerical rating scale ≥ 4 * patient in stable clinical situation on the next month (no surgery, radiotherapy, hormone therapy, chemotherapy or other treatment scheduled in the month following the enrollment) * patients affiliated to the french social security * patients with free and informed consent has been obtained exclusion criteria: * - hypersensitivity to the active substance or to any of the excipients * hypertension * history of stroke * severe heart failure * severe hepatic impairment * shortness of breath * congenital galactosemia, glucose-galactose malabsorption, lactase deficiency * association with linezolid * pre-existence or history of peripheral neuropathy due to a cause different from neurotoxic chemotherapy * diabetes (type i and ii) * medical and surgical history incompatible with the study * patient receiving treatment with amantadine, ketamine, memantine, l-dopa, dopaminergic agonists, anticholinergics, barbiturates, neuroleptics, monoamine oxidase inhibitor, dantrolene or baclofen, phenytoin, cimetidine, ranitidine, procainamide, quinidine, quinine, amiodarone, fluoxetine, paroxetine, propafenone, thioridazine, ritonavir, nicotine, hydrochlorothiazide, warfarin * present or past psychotropic substances and alcohol dependence * childbearing age, no use of effective contraceptive method, pregnancy or lactation * patient exclusion period, or the total allowable compensation exceeded * patients undergoing a measure of legal protection (guardianship, supervision ...)

Keywords: chemotherapy-induced peripheral neuropathy